# Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:

> **NCT02439320** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 2231 (actual)

## Conditions studied

- Acute Migraine

## Interventions

- **DRUG:** Lasmiditan 100 mg
- **DRUG:** Lasmiditan 200 mg
- **DRUG:** Placebo (matches lasmiditan doses)

## Key facts

- **NCT ID:** NCT02439320
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-07
- **Final completion:** 2016-08
- **Target enrollment:** 2231 (ACTUAL)
- **Last updated:** 2019-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02439320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02439320, "Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02439320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*